Posted on

cbd oil and schizophrenia

The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis

Affiliations

  • 1 219 Military Hospital, Didymοticho, Greece.
  • 2 3rd Department of Psychiatry, University Hospital AHEPA, School of Medicine, Aristotle University of Thessaloniki, Greece; Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.
  • 3 Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.
  • 4 1st Department of Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • 5 Department of Clinical Pharmacology, Department of Medicine, School of Medicine, Faculty of Health Sciences, School of Health Sciences, Aristotle University, University Campus, 54124, Thessaloniki, Greece.
  • 6 Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece. Electronic address: [email protected]
  • PMID: 32599446
  • DOI: 10.1016/j.psychres.2020.113246

The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis

  • Search in PubMed
  • Search in NLM Catalog
  • Add to Search

Authors

Affiliations

  • 1 219 Military Hospital, Didymοticho, Greece.
  • 2 3rd Department of Psychiatry, University Hospital AHEPA, School of Medicine, Aristotle University of Thessaloniki, Greece; Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.
  • 3 Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.
  • 4 1st Department of Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • 5 Department of Clinical Pharmacology, Department of Medicine, School of Medicine, Faculty of Health Sciences, School of Health Sciences, Aristotle University, University Campus, 54124, Thessaloniki, Greece.
  • 6 Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece. Electronic address: [email protected]
  • PMID: 32599446
  • DOI: 10.1016/j.psychres.2020.113246

Abstract

The purpose of the present meta-analysis was to assess the efficacy of cannabidiol (CBD) oil in patients with schizophrenia. A search was conducted in EMBASE, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov and WHO International Clinical Trials Registry Platform (ICTRP) up to April 24th, 2020. Randomized clinical trials (RCTs), which used CBD oil treatment versus placebo or any other antipsychotic in schizophrenia patients either as monotherapy or add-on therapy, were included. Data were pooled using a random-effects model. The primary outcomes were efficacy as measured by total symptoms of schizophrenia and improvement in cognition. The meta-analysis was registered with PROSPERO [number: CRD42020157146]. Three double-blind RCTs were included. In one study, CBD oil was compared with amisulpride as monotherapy treatment, but no statistically significant difference in overall efficacy was detected between them. No data were available for cognition. The other two studies estimated the effects of CBD oil as add-on treatment compared to placebo; no significant difference was found either in overall efficacy or in cognition. Altogether, insufficient evidence exists on the efficacy and safety of CBD oil in schizophrenia patients. More RCTs, comparing CBD oil with placebo and other antipsychotics are warranted.

Keywords: Antipsychotic drugs; Cbd; Psychosis.

Copyright © 2020 Elsevier B.V. All rights reserved.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no conflicts of interest.

The purpose of the present meta-analysis was to assess the efficacy of cannabidiol (CBD) oil in patients with schizophrenia. A search was conducted in EMBASE, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov and WHO International Clinical Trials Registry Platform …

The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis

Add to Mendeley

Highlights

In monotherapy treatment, cannabidiol oil did not show any significant difference compared to amisulpride with respect to overall efficacy (MD −0.40, 95% CI −14.22 to 13.42).

In the add-on therapy, cannabidiol oil was not significantly better compared to placebo in terms of overall efficacy (MD −1.07, 95% CI −2.64 to 0.49).

In the add-on therapy, there was not a significant difference between cannabidiol oil and placebo regarding cognition (SMD 0.09, 95% CI −0.27 to 0.45).

Further studies are needed to confirm the potential of cannabidiol oil in schizophrenia treatment.

Abstract

The purpose of the present meta-analysis was to assess the efficacy of cannabidiol (CBD) oil in patients with schizophrenia. A search was conducted in EMBASE, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov and WHO International Clinical Trials Registry Platform (ICTRP) up to April 24th, 2020. Randomized clinical trials (RCTs), which used CBD oil treatment versus placebo or any other antipsychotic in schizophrenia patients either as monotherapy or add-on therapy, were included. Data were pooled using a random-effects model. The primary outcomes were efficacy as measured by total symptoms of schizophrenia and improvement in cognition. The meta-analysis was registered with PROSPERO [number: CRD42020157146]. Three double-blind RCTs were included. In one study, CBD oil was compared with amisulpride as monotherapy treatment, but no statistically significant difference in overall efficacy was detected between them. No data were available for cognition. The other two studies estimated the effects of CBD oil as add-on treatment compared to placebo; no significant difference was found either in overall efficacy or in cognition. Altogether, insufficient evidence exists on the efficacy and safety of CBD oil in schizophrenia patients. More RCTs, comparing CBD oil with placebo and other antipsychotics are warranted.

Previous article in issue
Next article in issue

The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis Add to Mendeley Highlights In monotherapy treatment, cannabidiol oil did not show any